Literature DB >> 11567746

Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections.

A Ghosh1, W W Zhang, G Matlashewski.   

Abstract

The A2 genes of Leishmania donovani encode amastigote-specific A2 proteins, which are considered to be virulence factors required for the survival of this protozoan parasite in the mammalian host. The A2 genes are present within a multigene family and corresponding A2 proteins are composed predominantly of multiple copies of a 10 amino acid repeat sequences. A2-specific antibodies have been detected in the sera of patients suffering from visceral leishmaniasis (VL) and it has been shown that generation of A2 deficient L. donovani resulted in an avirulent phenotype. In this report, we show that immunization of mice with recombinant A2 protein conferred significant protection against challenge infection with L. donovani. The protection correlated with in vitro splenocyte proliferation, production of IFN-gamma in response to A2 protein and the presence of A2-specific antibodies in the sera of immunized mice. These data demonstrate that A2 represents a potential antigen for protection against infection with L. donovani and VL.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11567746     DOI: 10.1016/s0264-410x(01)00322-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  50 in total

1.  KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis.

Authors:  Yasuyuki Goto; Ajay Bhatia; Vanitha S Raman; Hong Liang; Raodoh Mohamath; Alessandro F Picone; Silvia E Z Vidal; Thomas S Vedvick; Randall F Howard; Steven G Reed
Journal:  Clin Vaccine Immunol       Date:  2011-06-01

2.  Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection.

Authors:  Yasuyuki Goto; Ajay Bhatia; Vanitha S Raman; Silvia E Z Vidal; Sylvie Bertholet; Rhea N Coler; Randall F Howard; Steven G Reed
Journal:  Vaccine       Date:  2009-03-09       Impact factor: 3.641

3.  Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant.

Authors:  Yasuyuki Goto; Lisa Y Bogatzki; Sylvie Bertholet; Rhea N Coler; Steven G Reed
Journal:  Vaccine       Date:  2007-08-20       Impact factor: 3.641

4.  Identification of Leishmania infantum chagasi proteins in urine of patients with visceral leishmaniasis: a promising antigen discovery approach of vaccine candidates.

Authors:  S S Kashino; C Abeijon; L Qin; K A Kanunfre; F S Kubrusly; F O Silva; D L Costa; D Campos; C H N Costa; I Raw; A Campos-Neto
Journal:  Parasite Immunol       Date:  2012-07       Impact factor: 2.280

5.  Evaluation of ex vivo human immune response against candidate antigens for a visceral leishmaniasis vaccine.

Authors:  Rajiv Kumar; Yasuyuki Goto; Kamlesh Gidwani; Karen D Cowgill; Shyam Sundar; Steven G Reed
Journal:  Am J Trop Med Hyg       Date:  2010-05       Impact factor: 2.345

6.  Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome.

Authors:  Garry L Morefield; Lynn D Hawkins; Sally T Ishizaka; Teri L Kissner; Robert G Ulrich
Journal:  Clin Vaccine Immunol       Date:  2007-08-22

7.  Molecular Analysis of A2-genes Encoding Stage-specific S Antigen-like Proteins among Isolates from Iranian Cutaneous and Visceral Leishmaniasis.

Authors:  Mahin Farahmand; Hasti Atashi Shirazi; Hossein Nahrevanian; Homa Hajjaran
Journal:  Iran J Basic Med Sci       Date:  2011-09       Impact factor: 2.699

8.  Distinct antigen recognition pattern during zoonotic visceral leishmaniasis in humans and dogs.

Authors:  Yasuyuki Goto; Randall F Howard; Ajay Bhatia; Joelma Trigo; Maria Nakatani; Eduardo M Netto; Steven G Reed
Journal:  Vet Parasitol       Date:  2008-11-05       Impact factor: 2.738

9.  Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis.

Authors:  Rajesh Ravindran; Sudipta Bhowmick; Amrita Das; Nahid Ali
Journal:  BMC Microbiol       Date:  2010-06-24       Impact factor: 3.605

10.  Kinesin motor domain of Leishmania donovani as a future vaccine candidate.

Authors:  Ayan Dey; Pawan Sharma; Naresh Singh Redhu; Sarman Singh
Journal:  Clin Vaccine Immunol       Date:  2008-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.